standard of care in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results Sekine (PLACOVID), 2021 (REV) 0.47 [0.15; 1.43]
0.47 [0.15 ; 1.43 ] Sekine (PLACOVID), 2021 (REV) 1 0% 160 NA not evaluable death D28detailed results AlQahtani, 2020 (REV) 2.11 [0.18; 25.35]
Li, 2020 (REV) 1.69 [0.63; 4.56]
Pouladzadeh, 2021 (REV) 3.28 [0.10; 109.64]
RECOVER, 2021 (REV) 0.92 [0.32; 2.63]
Sekine (PLACOVID), 2021 (REV) 0.72 [0.38; 1.38]
0.98 [0.61 ; 1.56 ] AlQahtani, 2020 (REV), Li, 2020 (REV), Pouladzadeh, 2021 (REV), RECOVER, 2021 (REV), Sekine (PLACOVID), 2021 (REV) 5 0% 451 moderate not evaluable deathsdetailed results AlQahtani, 2020 (REV) 2.11 [0.18; 25.35]
CAPSID, 2021 (REV) 1.19 [0.40; 3.57]
CP-COVID-19, 2021 (REV) 0.31 [0.06; 1.60]
Li, 2020 (REV) 1.69 [0.63; 4.56]
Pouladzadeh, 2021 (REV) 3.28 [0.10; 109.64]
Rasheed, 2020 (REV) 8.00 [0.91; 70.02]
RECOVER, 2021 (REV) 0.92 [0.32; 2.63]
REMAP-CAP (plasma), 2021 (REV) 1.05 [0.87; 1.26]
Sekine (PLACOVID), 2021 (REV) 0.72 [0.38; 1.38]
1.04 [0.82 ; 1.31 ] AlQahtani, 2020 (REV), CAPSID, 2021 (REV), CP-COVID-19, 2021 (REV), Li, 2020 (REV), Pouladzadeh, 2021 (REV), Rasheed, 2020 (REV), RECOVER, 2021 (REV), REMAP-CAP (plasma), 2021 (REV), Sekine (PLACOVID), 2021 (REV) 9 6% 2,684 low not evaluable deaths (time to event analysis only)detailed results CP-COVID-19, 2021 (REV) 0.31 [0.06; 1.60]
0.31 [0.06 ; 1.60 ] CP-COVID-19, 2021 (REV) 1 0% 100 NA not evaluable clinical deteriorationdetailed results CAPSID, 2021 (REV) 1.58 [0.71; 3.49]
1.58 [0.71 ; 3.49 ] CAPSID, 2021 (REV) 1 0% 105 NA not evaluable clinical improvementdetailed results CAPSID, 2021 (REV) 0.63 [0.29; 1.40]
Li, 2020 (REV) 0.71 [0.40; 1.27]
Pouladzadeh, 2021 (REV) 0.14 [0.03; 0.62]
Sekine (PLACOVID), 2021 (REV) 1.06 [0.84; 1.35]
0.69 [0.40 ; 1.19 ] CAPSID, 2021 (REV), Li, 2020 (REV), Pouladzadeh, 2021 (REV), Sekine (PLACOVID), 2021 (REV) 4 67% 428 moderate not evaluable clinical improvement (14-day)detailed results Li, 2020 (REV) 0.44 [0.17; 1.11]
0.44 [0.17 ; 1.11 ] Li, 2020 (REV) 1 0% 103 NA not evaluable clinical improvement (28-day)detailed results Li, 2020 (REV) 0.70 [0.32; 1.54]
Pouladzadeh, 2021 (REV) 0.14 [0.03; 0.62]
Sekine (PLACOVID), 2021 (REV) 1.06 [0.84; 1.35]
0.62 [0.27 ; 1.46 ] Li, 2020 (REV), Pouladzadeh, 2021 (REV), Sekine (PLACOVID), 2021 (REV) 3 74% 323 moderate not evaluable clinical improvement (7-day)detailed results Li, 2020 (REV) 1.02 [0.28; 3.73]
1.02 [0.28 ; 3.73 ] Li, 2020 (REV) 1 0% 103 NA not evaluable clinical improvement (time to event analysis only)detailed results Li, 2020 (REV) 0.71 [0.40; 1.27]
0.71 [0.40 ; 1.27 ] Li, 2020 (REV) 1 0% 103 NA not evaluable mechanical ventilationdetailed results AlQahtani, 2020 (REV) 1.49 [0.50; 4.50]
1.49 [0.50 ; 4.50 ] AlQahtani, 2020 (REV) 1 0% 40 NA not evaluable mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 (REV) 1.52 [0.58; 3.95]
1.52 [0.58 ; 3.95 ] CP-COVID-19, 2021 (REV) 1 0% 100 NA not evaluable viral clearance detailed results CP-COVID-19, 2021 (REV) 0.89 [0.13; 6.25]
0.89 [0.13 ; 6.25 ] CP-COVID-19, 2021 (REV) 1 0% 100 NA not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 (REV) 0.66 [0.14; 3.05]
0.66 [0.14 ; 3.05 ] CP-COVID-19, 2021 (REV) 1 0% 100 NA not evaluable ICU admissiondetailed results CP-COVID-19, 2021 (REV) 1.22 [0.52; 2.84]
1.22 [0.52 ; 2.84 ] CP-COVID-19, 2021 (REV) 1 0% 100 NA not evaluable serious adverse eventsdetailed results REMAP-CAP (plasma), 2021 (REV) 0.44 [0.22; 0.86]
Sekine (PLACOVID), 2021 (REV) 0.88 [0.68; 1.14]
0.67 [0.34 ; 1.30 ] REMAP-CAP (plasma), 2021 (REV), Sekine (PLACOVID), 2021 (REV) 2 72% 2,140 moderate not evaluable adverse eventsdetailed results Sekine (PLACOVID), 2021 (REV) 0.93 [0.73; 1.18]
0.93 [0.73 ; 1.18 ] Sekine (PLACOVID), 2021 (REV) 1 0% 160 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-15 04:26 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
